China's National Medical Products Administration included Kexing Biopharm (SHA:688136) unit Shenzhen Sinovac Pharmaceutical's recombinant human interferon a1b inhalation solution in its breakthrough therapy designation list, according to a Shanghai bourse filing on Wednesday.
Drugs under the list are provided with priority resources for their development.
The drug, which is currently in phase III clinical trials, is used to treat children with lower respiratory tract infections caused by respiratory syncytial virus.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments